checkAd

    DGAP-News  143  0 Kommentare DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS - Seite 3



    Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

    20.09.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de

    Language: English
    Company: Defence Therapeutics Inc.
    1680 - 200 Burrard St
    V6C3L6 Vancouver
    Canada
    E-mail: info@defencetherapeutics.com
    Internet: https://defencetherapeutics.com
    ISIN: CA24463V1013
    WKN: A3CN14
    Listed: Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto
    EQS News ID: 1234347

     
    End of News DGAP News Service

    Lesen Sie auch

    1234347  20.09.2021 

    fncls.ssp?fn=show_t_gif&application_id=1234347&application_name=news&site_id=wallstreet
    Seite 3 von 3



    Diskutieren Sie über die enthaltenen Werte



    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS - Seite 3 DGAP-News: Defence Therapeutics Inc. / Key word(s): Miscellaneous DEFENCE THERAPEUTICS SUCCESSFULLY ENGINEERED AND TESTED A NOVEL INTRANASAL COVID-19 VACCINE FORMULATION IN ANIMALS 20.09.2021 / 08:30 The issuer is solely responsible for the …

    Artikel zu den Werten

    Auch bei Lesern beliebt

    Schreibe Deinen Kommentar

    Disclaimer